Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency


Kiykim A., Ogulur I., Dursun E., Charbonnier L., Nain E., Cekic S., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, vol.7, no.8, pp.2790-2815, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.1016/j.jaip.2019.06.011
  • Title of Journal : JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
  • Page Numbers: pp.2790-2815

Abstract

BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.